EVOLVE-101

N/A

Report date: 2023/07/26 18:00:31
First In Class

Base Information

Drug NameEVOLVE-101
Drug Alias NameEVOLVE-101
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionImmunologic cytotoxicityT lymphocytes stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsUpdating
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEvolveImmune Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEvolveImmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A